Akari Therapeutics (AKTX) Capital Expenditures (2016)

Akari Therapeutics (AKTX) posted quarterly Capital Expenditures of $5897.0 for Q2 2016, down 85.99% on a QoQ basis from $42083.0 in Q1 2016.

Akari Therapeutics (AKTX) Capital Expenditures (2016) Analysis & Trends

Akari Therapeutics (AKTX) has reported Capital Expenditures for 1 consecutive years, with $5897.0 the latest figure, recorded in Q2 2016.

Quarterly Capital Expenditures changed N/A year-over-year to $5897.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $47980.0 (changed N/A YoY) and the FY2017 annual result came in at $36885.0, down 32.63% from the prior year.
Capital Expenditures fell to $5897.0 in Q2 2016 per AKTX's latest filing, from $42083.0 in the prior quarter.
Over the last five years, Capital Expenditures for AKTX reached as high as $42083.0 in Q1 2016 and fell as low as $5897.0 in Q2 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Akari Therapeutics	86.55 Mn	86.55 Mn	-	-

Download Data